全文获取类型
收费全文 | 35990篇 |
免费 | 7869篇 |
国内免费 | 1328篇 |
专业分类
耳鼻咽喉 | 743篇 |
儿科学 | 766篇 |
妇产科学 | 922篇 |
基础医学 | 1862篇 |
口腔科学 | 2900篇 |
临床医学 | 6101篇 |
内科学 | 7127篇 |
皮肤病学 | 584篇 |
神经病学 | 2492篇 |
特种医学 | 1532篇 |
外国民族医学 | 1篇 |
外科学 | 5117篇 |
综合类 | 3037篇 |
现状与发展 | 14篇 |
一般理论 | 1篇 |
预防医学 | 3955篇 |
眼科学 | 643篇 |
药学 | 1884篇 |
22篇 | |
中国医学 | 1561篇 |
肿瘤学 | 3923篇 |
出版年
2024年 | 212篇 |
2023年 | 1516篇 |
2022年 | 1255篇 |
2021年 | 1811篇 |
2020年 | 2137篇 |
2019年 | 1196篇 |
2018年 | 2022篇 |
2017年 | 1975篇 |
2016年 | 2083篇 |
2015年 | 2514篇 |
2014年 | 2962篇 |
2013年 | 3291篇 |
2012年 | 2024篇 |
2011年 | 1985篇 |
2010年 | 2216篇 |
2009年 | 2587篇 |
2008年 | 1452篇 |
2007年 | 1163篇 |
2006年 | 1267篇 |
2005年 | 987篇 |
2004年 | 674篇 |
2003年 | 651篇 |
2002年 | 505篇 |
2001年 | 644篇 |
2000年 | 518篇 |
1999年 | 569篇 |
1998年 | 654篇 |
1997年 | 605篇 |
1996年 | 626篇 |
1995年 | 465篇 |
1994年 | 379篇 |
1993年 | 302篇 |
1992年 | 222篇 |
1991年 | 200篇 |
1990年 | 193篇 |
1989年 | 179篇 |
1988年 | 158篇 |
1987年 | 143篇 |
1986年 | 114篇 |
1985年 | 101篇 |
1984年 | 78篇 |
1983年 | 91篇 |
1982年 | 82篇 |
1981年 | 67篇 |
1980年 | 47篇 |
1979年 | 33篇 |
1978年 | 32篇 |
1977年 | 43篇 |
1976年 | 31篇 |
1975年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
痛情绪是指因疼痛引发的情绪和情感体验,是疾病过程中最常见的一种情绪。痛情绪相关神经机制非常复杂,但主要与单胺类神经递质、神经肽和某些神经环路有关,笔者将结合目前研究现状分别从以上两方面展开,就痛情绪相关单胺类神经递质和神经肽在受体分类、脑区通路、共疾病以及各神经递质之间的联系和痛情绪相关神经环路中各个蛋白的作用机制等方面进行探讨。 相似文献
3.
4.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
5.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
6.
Haochu Li Xiaoming Li Lai Sze Tso Shan Qiao Eleanor Holroyd Yuejiao Zhou 《Vulnerable children and youth studies》2016,11(2):173-179
In HIV/AIDS research, few studies to date have evaluated ways to improve parental HIV disclosure practices using feedback from HIV-negative children who have recently experienced this event. We conducted semi-structured in-depth interviews with 20 children (aged 6–15) who were partially to fully aware of their parents’ HIV status in rural Guangxi, China. Of the 20 children, eight children who were of older age (11.38 years in average) endorsed parental HIV disclosure, five discouraged it and seven expressed uncertainty. Children’s different experiences and attitudes towards disclosure were seen to be associated with their family dynamics (especially the parent–child relationship), social support and care, experiences of stigma and discrimination, psychosocial suffering, comprehension of the disease and the children’s age. Our study contributes to building a child-centered comprehensive understanding for Chinese parental HIV disclosure. It is imperative that counselors and community advocates assess and help parents achieve optimal readiness preceding disclosure of their illness to their HIV-negative children. 相似文献
7.
8.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献9.
10.